Studies showing that IDO expression was also connected with resistance to anti-CTLA-4 antibodies in mice tumor models demonstrated the importance of IDO as a possible biomarker for the enrolment of cancer patients into immunotherapeutic regimens [46]. The gene discussed is IDO1; the disease is cancer.